Ontology highlight
ABSTRACT:
SUBMITTER: Lyseng-Williamson KA
PROVIDER: S-EPMC6267530 | biostudies-other | 2018
REPOSITORIES: biostudies-other
Lyseng-Williamson Katherine A KA
Drugs & therapy perspectives : for rational drug selection and use 20181031 12
The EU indication for anakinra has been extended to include Still's disease, a serious rare inflammatory disorder of unknown aetiology that comprises adult-onset Still's disease (AOSD) and systemic juvenile idiopathic arthritis (SJIA). As activated interleukin-1 pathways are associated with the systemic manifestations of these disorders, targeted treatment with anakinra, an interleukin-1 inhibitor, has been investigated. Across clinical and real-world studies in patients with AOSD and SJIA, trea ...[more]